Chicago Equity Partners LLC Has $649,000 Stake in USANA Health Sciences, Inc. (USNA)

Chicago Equity Partners LLC decreased its holdings in USANA Health Sciences, Inc. (NYSE:USNA) by 8.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,515 shares of the company’s stock after selling 510 shares during the quarter. Chicago Equity Partners LLC’s holdings in USANA Health Sciences were worth $649,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Flagship Harbor Advisors LLC raised its position in USANA Health Sciences by 60.8% in the fourth quarter. Flagship Harbor Advisors LLC now owns 677 shares of the company’s stock worth $79,000 after acquiring an additional 256 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in USANA Health Sciences by 23.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 858 shares of the company’s stock worth $101,000 after acquiring an additional 165 shares in the last quarter. Harvest Fund Management Co. Ltd raised its position in USANA Health Sciences by 418.6% in the third quarter. Harvest Fund Management Co. Ltd now owns 1,224 shares of the company’s stock worth $148,000 after acquiring an additional 988 shares in the last quarter. Janus Henderson Group PLC purchased a new position in USANA Health Sciences in the third quarter worth $258,000. Finally, Jefferies Group LLC purchased a new position in USANA Health Sciences in the third quarter worth $334,000. Hedge funds and other institutional investors own 53.99% of the company’s stock.

Shares of USNA stock opened at $105.04 on Tuesday. USANA Health Sciences, Inc. has a fifty-two week low of $75.20 and a fifty-two week high of $137.95. The firm has a market capitalization of $2.52 billion, a PE ratio of 20.36 and a beta of 0.53.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, February 5th. The company reported $1.32 earnings per share for the quarter, missing analysts’ consensus estimates of $1.33 by ($0.01). USANA Health Sciences had a net margin of 10.61% and a return on equity of 29.94%. The firm had revenue of $299.02 million during the quarter, compared to analysts’ expectations of $305.79 million. During the same quarter in the prior year, the business earned $1.11 EPS. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. As a group, sell-side analysts forecast that USANA Health Sciences, Inc. will post 5.4 EPS for the current year.

USANA Health Sciences announced that its board has approved a share repurchase plan on Tuesday, October 23rd that authorizes the company to buyback $150.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 5.9% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Several research analysts have issued reports on the company. Sidoti upgraded USANA Health Sciences from a “neutral” rating to a “buy” rating in a research report on Thursday, October 25th. Pivotal Research upgraded USANA Health Sciences from a “hold” rating to a “buy” rating and set a $135.00 price objective for the company in a research report on Wednesday, October 24th. Finally, ValuEngine cut USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, November 8th.

In other news, Director Feng Peng sold 282 shares of the firm’s stock in a transaction on Tuesday, November 27th. The stock was sold at an average price of $120.15, for a total value of $33,882.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Myron W. Wentz sold 30,000 shares of the firm’s stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $120.56, for a total value of $3,616,800.00. The disclosure for this sale can be found here. In the last 90 days, insiders bought 19,117 shares of company stock valued at $1,349,965 and sold 178,861 shares valued at $20,032,300. Company insiders own 48.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Chicago Equity Partners LLC Has $649,000 Stake in USANA Health Sciences, Inc. (USNA)” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.themarketsdaily.com/2019/02/19/chicago-equity-partners-llc-has-649000-stake-in-usana-health-sciences-inc-usna.html.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Featured Article: Convertible Shares

Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).

Institutional Ownership by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.